Details for Patent: 8,758,776
✉ Email this page to a colleague
Title: | Compositions and methods for treatment |
Abstract: | The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists. |
Inventor(s): | Oslob; Johan (Sunnyvale, CA), Shen; Wang (San Mateo, CA), Barr; Kenneth (Boston, MA), Zhong; Min (Palo Alto, CA) |
Assignee: | Sarcode Bioscience Inc. (Brisbane, CA) |
Filing Date: | Jan 21, 2011 |
Application Number: | 13/011,775 |
Claims: | 1. A pharmaceutical composition comprising an effective amount of a compound having the following formula: ##STR00037## or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle, wherein the composition is in the form of liquid drops, liquid wash, gel, ointment, liposomes, solution, cream, powder, foam, crystals, spray, aerosol, or liquid suspension. 2. A pharmaceutical composition comprising an effective amount of a compound having the following formula: ##STR00038## or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable vehicle, wherein the pharmaceutically acceptable vehicle is suitable for ocular administration, and further wherein the composition is formulated as an insert, implant, subconjunctival injection, intraocular injection, periocular injection, retrobulbar injection, or intracameral injection. 3. The pharmaceutical composition of claim 2 wherein the insert or implant comprises a selective release device comprising a formulation wherein the compound is released in a sustained fashion. 4. The pharmaceutical composition of claim 3 wherein the formulation comprises a biocompatible polymer. 5. The pharmaceutical composition of claim 2, further comprising a preservative. 6. The pharmaceutical composition of claim 1, further comprising a preservative. 7. The pharmaceutical composition of claim 1, wherein the composition is in the form of liquid drops. 8. The pharmaceutical composition of claim 1, wherein the composition is in the form of a liquid wash. 9. The pharmaceutical composition of claim 1, wherein the composition is in the form of a gel. 10. The pharmaceutical composition of claim 1, wherein the composition is in the form of an ointment. 11. The pharmaceutical composition of claim 1, wherein the composition is in the form of liposomes. 12. The pharmaceutical composition of claim 1, wherein the composition is in the form of a solution. 13. The pharmaceutical composition of claim 1, wherein the composition is in the form of a cream. 14. The pharmaceutical composition of claim 1, wherein the composition is in the form of a powder. 15. The pharmaceutical composition of claim 1, wherein the composition is in the form of a foam. 16. The pharmaceutical composition of claim 1, wherein the composition is in the form of crystals. 17. The pharmaceutical composition of claim 1, wherein the composition is in the form of a spray. 18. The pharmaceutical composition of claim 1, wherein the composition is in the form of an aerosol. 19. The pharmaceutical composition of claim 1, wherein the composition is in the form of a liquid suspension. |